aclaris
therapeutics
reports
third
quarter
financial
results
provides
corporate
update
first
subject
dosed
phase
trial
investigational
topical
soft
jak
inhibitor
treatment
moderate
severe
atopic
dermatitis
initiated
phase
trial
investigational
oral
inhibitor
treatment
periodic
syndrome
caps
wayne
globe
newswire
aclaris
therapeutics
nasdaq
acrs
biopharmaceutical
company
focused
developing
novel
drug
candidates
diseases
today
announced
financial
results
third
quarter
provided
corporate
update
continued
meet
milestones
meaningfully
advance
pipeline
said
neal
walker
president
ceo
aclaris
recently
announced
dosed
first
subject
phase
trial
treatment
moderate
severe
atopic
dermatitis
addition
initiated
phase
trial
potential
treatment
periodic
syndrome
orphan
indication
look
forward
progressing
trials
well
ongoing
trial
rheumatoid
research
development
highlights
global
outbreak
continues
rapidly
evolve
caused
may
continue
cause
aclaris
experience
disruptions
could
impact
timing
research
development
regulatory
activities
listed
ati
investigational
oral
small
molecule
inhibitor
compound
ongoing
phase
clinical
trial
investigate
safety
tolerability
pharmacokinetics
pharmacodynamics
subjects
moderate
severe
rheumatoid
arthritis
aclaris
planned
enrollment
trial
subjects
aclaris
anticipates
reporting
data
trial
first
half
ongoing
phase
clinical
trial
investigate
safety
tolerability
efficacy
pharmacodynamics
maintenance
remission
subjects
periodic
syndrome
caps
previously
managed
therapy
aclaris
planned
enrollment
trial
subjects
primary
endpoint
trial
assessment
safety
tolerability
key
secondary
efficacy
endpoint
trial
proportion
subjects
maintain
disease
remission
aclaris
initiated
trial
filed
orphan
drug
designation
indication
november
ongoing
phase
randomized
clinical
trial
investigate
safety
efficacy
used
addition
standard
care
therapy
potential
treatment
cytokine
release
syndrome
approximately
hospitalized
patients
aclaris
providing
funding
clinical
drug
supply
university
kansas
medical
center
kumc
sponsor
trial
primary
endpoint
trial
proportion
subjects
free
respiratory
failure
day
investigational
oral
small
molecule
inhibitor
compound
investigational
topical
soft
janus
kinase
jak
inhibitor
compound
ongoing
phase
multicenter
randomized
clinical
trial
investigate
efficacy
safety
tolerability
pharmacokinetics
subjects
moderate
severe
atopic
dermatitis
aclaris
planned
enrollment
trial
approximately
subjects
primary
endpoint
percentage
change
baseline
eczema
area
severity
index
easi
score
week
first
subject
dosed
october
investigational
topical
soft
janus
kinase
jak
inhibitor
compound
investigational
oral
itk
txk
itj
inhibitor
compound
aclaris
developing
potential
treatment
psoriasis
inflammatory
bowel
disease
expects
submit
investigational
new
drug
ind
application
investigational
oral
itk
txk
itj
inhibitor
compound
business
development
highlights
aclaris
continues
pursue
strategic
alternatives
including
seeking
partners
topical
solution
obtain
regulatory
approval
commercialize
topical
solution
investigational
compound
potential
treatment
common
warts
verruca
vulgaris
develop
obtain
regulatory
approval
commercialize
oral
topical
investigational
jak
inhibitor
compounds
potential
treatments
alopecia
eskata
commercialize
hydrogen
peroxide
topical
solution
w
w
financial
highlights
liquidity
capital
resources
september
aclaris
aggregate
cash
cash
equivalents
restricted
cash
marketable
securities
million
compared
million
december
three
nine
months
ended
september
net
cash
used
operating
activities
million
million
respectively
september
aclaris
approximately
million
shares
common
stock
outstanding
august
aclaris
entered
equity
purchase
agreement
lincoln
park
capital
fund
llc
lincoln
park
agreement
allows
aclaris
sell
discretion
million
common
stock
lincoln
park
aclaris
anticipates
cash
cash
equivalents
restricted
cash
marketable
securities
september
sufficient
fund
operations
first
quarter
without
giving
effect
potential
business
development
transactions
financing
activities
third
quarter
financial
results
accompanying
condensed
consolidated
statements
operations
selected
consolidated
balance
sheet
data
recast
periods
presented
reflect
assets
liabilities
revenue
expenses
related
aclaris
commercial
products
discontinued
operations
net
loss
million
third
quarter
compared
million
third
quarter
million
nine
months
ended
september
compared
million
nine
months
ended
september
total
revenue
million
third
quarter
compared
million
third
quarter
million
nine
months
ended
september
compared
million
nine
months
ended
september
research
development
r
expenses
million
quarter
ended
september
compared
million
prior
year
period
million
nine
months
ended
september
compared
million
prior
year
period
decrease
million
primarily
result
substantial
completion
aclaris
various
phase
clinical
trials
two
pivotal
phase
clinical
trials
topical
solution
corresponding
reduction
personnel
costs
support
programs
additionally
aclaris
made
million
milestone
payment
achievement
development
milestone
third
quarter
also
contributed
decrease
r
expenses
third
quarter
included
compensation
expense
million
compared
million
prior
year
period
general
administrative
g
expenses
million
quarter
ended
september
compared
million
prior
year
period
million
nine
months
ended
september
compared
million
prior
year
period
decrease
million
primarily
result
lower
personnel
costs
resulting
aclaris
decision
discontinue
commercial
operations
september
g
expenses
third
quarter
included
compensation
expense
million
compared
million
prior
year
period
loss
continuing
operations
million
quarter
ended
september
compared
million
prior
year
period
million
nine
months
ended
september
compared
million
prior
year
period
loss
discontinued
operations
third
quarter
compared
million
third
quarter
million
nine
months
ended
september
compared
million
nine
months
ended
september
aclaris
therapeutics
aclaris
therapeutics
biopharmaceutical
company
developing
pipeline
novel
drug
candidates
address
needs
patients
diseases
lack
satisfactory
treatment
options
company
portfolio
drug
candidates
powered
robust
r
engine
exploring
protein
kinase
regulation
additional
information
please
visit
cautionary
note
regarding
statements
statements
contained
press
release
describe
historical
facts
may
constitute
statements
term
defined
private
securities
litigation
reform
act
statements
may
identified
words
believe
expect
intend
may
plan
potential
similar
expressions
based
aclaris
current
beliefs
expectations
statements
include
expectations
regarding
clinical
development
aclaris
drug
candidates
including
availability
data
clinical
trials
timing
regulatory
filings
plan
pursue
strategic
alternatives
drug
candidates
eskata
belief
existing
cash
cash
equivalents
restricted
cash
marketable
securities
sufficient
fund
operations
first
quarter
statements
involve
risks
uncertainties
could
cause
actual
results
differ
materially
reflected
statements
risks
uncertainties
may
cause
actual
results
differ
materially
include
uncertainties
inherent
conduct
clinical
trials
aclaris
reliance
third
parties
may
always
full
control
aclaris
ability
enter
strategic
partnerships
commercially
reasonable
terms
uncertainty
regarding
pandemic
risks
uncertainties
described
risk
factors
section
aclaris
annual
report
form
year
ended
december
aclaris
quarterly
report
form
quarter
ended
september
filings
aclaris
makes
securities
exchange
commission
time
time
documents
available
sec
filings
page
investors
section
aclaris
website
http
statements
speak
date
press
release
based
information
available
aclaris
date
release
aclaris
assumes
obligation
intend
update
statements
whether
result
new
information
future
events
otherwise
aclaris
therapeutics
condensed
consolidated
statements
operations
unaudited
thousands
except
share
per
share
data
three
months
ended
nine
months
ended
september
september
revenues
contract
research
revenue
total
revenue
costs
expenses
cost
revenue
research
development
general
administrative
goodwill
impairment
total
costs
expenses
loss
operations
expense
net
loss
continuing
operations
loss
discontinued
operations
net
loss
net
loss
per
share
basic
diluted
weighted
average
common
shares
outstanding
basic
diluted
amounts
include
compensation
expense
follows
cost
revenue
research
development
general
administrative
loss
discontinued
operations
total
compensation
expense
aclaris
therapeutics
inc
selected
consolidated
balance
sheet
data
unaudited
thousands
september
december
cash
cash
equivalents
restricted
cash
marketable
securities
total
assets
total
current
liabilities
total
liabilities
total
stockholders
equity
aclaris
contact
investors
